

## Daftar Pustaka

- Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. *J Clin Endocrinol Metab* 2008;93:611–8. doi:10.1210/jc.2007-1717.
- AIRTUM Working Group, CCM, AIEOP Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. *Epidemiol Prev n.d.*;37:1–225.
- Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. *Cancer* 2000;88:1902–8.
- Basolo, F., Torregrossa, L., Giannini, R., Miccoli, M., Lupi, C., Sensi, E., Berti, P., Elisei, R., Vitti, P., Baggiani, A., Miccoli, P., 2010. Correlation between the *BRAF* V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. *The Journal of Clinical Endocrinology & Metabolism* 95, 4197–4205. <https://doi.org/10.1210/jc.2010-0337>
- Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. *Mod Pathol* 2004;17:1359–63. doi:10.1038/modpathol.3800198.
- Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. *Otolaryngol Head Neck Surg* 2003;128:115–23. doi:10.1067/mhn.2003.2.
- Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* 2010;467:596–9. doi:10.1038/nature09454.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–



424. doi:10.3322/caac.21492.

Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab* 2008;93:504–15. doi:10.1210/jc.2007-1154.

Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. *Clin Cancer Res* 2011;17:7511–7. doi:10.1158/1078-0432.CCR-11-1155.

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2009;19:1167–214. doi:10.1089/thy.2009.0110.

Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P, De Micco C. Expression of tpo mRNA in thyroid tumors: Quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. *Endocr Relat Cancer* 2006;13:485–95. doi:10.1677/erc.1.01164.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949–54. doi:10.1038/nature00766.

Derwahl, M., Nicula, D., 2014. Estrogen and its role in thyroid cancer. *Endocrine Related Cancer* 21, T273–T283. <https://doi.org/10.1530/ERC-14-0053>

Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *J Clin Endocrinol Metab* 2007;92:2840–3. doi:10.1210/jc.2006-2707.

Galuppini F, Pennelli G, Ruge M. The rising incidence of papillary thyroid cancer: More cancers or more assessments? *Indian J Cancer* 2019;56:183–4. doi:10.4103/ijc.IJC\_483\_18.

Gautschi O, Milia J, Cabarro B, Bluthgen M-V, Besse B, Smit EF, et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. *J Thorac Oncol* 2015;10:1451–7. doi:10.1097/JTO.0000000000000625.



- Gawin, M., Kurczyk, A., Stobiecka, E., Frątczak, K., Polańska, J., Pietrowska, M., Widłak, P., 2019. Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging. *Endocr Pathol* 30, 250–261. <https://doi.org/10.1007/s12022-019-09593-2>
- Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. *Oncogene* 2005;24:6646–56. doi:10.1038/sj.onc.1208822.
- Goodarzi, Moslem A, Feizhadad H, Jarrahi AM, Adineh HA, Sohrabivafa M, et al. Epidemiology, incidence and mortality of thyroid cancer and their relationship with the human development index in the world: An ecology study in 2018. *Adv Hum Biol* 2019;9:162. doi:10.4103/AIHB.AIHB\_2\_19.
- Haugen Bryan R, Alexander Erik K, Bible Keith C, Doherty Gerard M, Mandel Susan J, Nikiforov Yuri E, FurioPacini, Randolph Gregory W, Sawka Anna M, Schlumberger Martin, Schuff KathrynG., Sherman Steven I, Sosa Julie Ann, Steward David L, Tuttle R. Michael, Wartofsky Leonard. 2015 America Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. *THYROID* Volume 26, Number 11, 2016. doi: 10.1089/thy.2015.0020.
- Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The Most Commonly Occurring Papillary Thyroid Cancer in the United States Is Now a Microcarcinoma in a Patient Older than 45 Years. *Thyroid* 2011;21:231–6. doi:10.1089/thy.2010.0137.
- Ji, W., Xie, H., Wei, B., Shen, H., Liu, A., Gao, Y. and Wang, L., 2019. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma. *International Journal of Clinical and Experimental Pathology*, 12(9), p.3492.
- Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, et al. Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in

- Papillary Thyroid Cancer. *J Clin Endocrinol Metab* 2006;91:3667–70.  
doi:10.1210/jc.2005-2836.
- Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O.H., Duh, Q.-Y., Shibru, D., Bastian, B., Griffin, A., 2007. The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer: *Annals of Surgery* 246, 466–471.  
<https://doi.org/10.1097/SLA.0b013e318148563d>
- Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. *Cancer Epidemiol Biomarkers Prev* 2009;18:1092–100.  
doi:10.1158/1055-9965.EPI-08-0976.
- Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. *Cancer* 2012;118:1764–73.  
doi:10.1002/cncr.26500.
- Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao X-H, et al. Targeted Expression of BRAF<sup>V600E</sup> in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation. *Cancer Res* 2005;65:4238–45. doi:10.1158/0008-5472.CAN-05-0047.
- Konturek A, Barczyński M, Nowak W, Richter P. Prognostic factors in differentiated thyroid cancer - A 20-year surgical outcome study. *Langenbeck's Arch Surg* 2012;397:809–15. doi:10.1007/s00423-011-0899-z.
- Koper JW, Lamberts SW. Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes. *Eur J Clin Invest* 2000;30:493–500.
- Krassas GE, Pontikides N. Gonadal effect of radiation from 131I in male patients with thyroid carcinoma. *Arch Androl* n.d.;51:171–5.
- Li, J., Zhang, S., Zheng, S., Zhang, D., Qiu, X., 2015. The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis 9.
- Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of



- BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. *Clin Cancer Res* 2007a;13:1341–9. doi:10.1158/1078-0432.CCR-06-1753.
- Liu D, Liu Z, Jiang D, Dackiw AP, Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. *J Clin Endocrinol Metab* 2007b;92:4686–95. doi:10.1210/jc.2007-0097.
- Lloyd, R.V., Osamura, R.Y., Klöppel, G., Rosai, J., International Agency for Research on Cancer, 2017. WHO Classification of Tumours of Endocrine Organs, IARC WHO Classification of Tumours Series. International Agency for Research on Cancer.
- Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab* 2007;92:4085–90. doi:10.1210/jc.2007-1179.
- Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. *Endocr Relat Cancer* 2001;8:219–25.
- Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. *Endocr Relat Cancer* 2016;23:313–22. doi:10.1530/ERC-15-0445.
- McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. *Surgery* 2001;130:1028–34. doi:10.1067/msy.2001.118266.
- McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. *Lancet* 2013;381:1046–57. doi:10.1016/S0140-6736(12)62205-3.
- Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, et al. Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling. *Cancer Res* 2006;66:6521–9. doi:10.1158/0008-5472.CAN-06-0739.
- Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, et al. Molecular



- characteristics in papillary thyroid cancers (PTCs) with no <sup>131</sup>I uptake. *Clin Endocrinol (Oxf)* 2008;68:108–16. doi:10.1111/j.1365-2265.2007.03008.x.
- Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. *Cancer Res* 2005;65:2465–73. doi:10.1158/0008-5472.CAN-04-3314.
- Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WMF. Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006). *Am J Pathol* 2006;169:1875–85. doi:10.2353/ajpath.2006.050711.
- Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. *J Clin Endocrinol Metab* 2003;88:4393–7. doi:10.1210/jc.2003-030305.
- Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. *J Clin Endocrinol Metab* 2003;88:5399–404. doi:10.1210/jc.2003-030838.
- Nilsson M. Iodide handling by the thyroid epithelial cell. *Exp Clin Endocrinol Diabetes* 2001;109:13–7. doi:10.1055/s-2001-11014.
- Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. *Thyroid* 2009;19:1077–84. doi:10.1089/thy.2009.0055.
- Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, et al. B-Raf (V600E) and thrombospondin-1 promote thyroid cancer progression. *Proc Natl Acad Sci* 2010;107 :10649–54. doi:10.1073/pnas.1004934107.
- Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, et al. Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo. *Clin Cancer Res* 2006;12:1785–93. doi:10.1158/1078-0432.CCR-05-1729.



- Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, et al. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. *Pediatr Res* 2002;52:737–44. doi:10.1203/00006450-200211000-00021.
- Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. *J Cancer Epidemiol* 2013;2013:1–10. doi:10.1155/2013/965212.
- Peyssonaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. *Biol Cell* 2001;93:53–62.
- Podolski, A., Castellucci, E., Halmos, B., 2019. Precision medicine: BRAF mutations in thyroid cancer. *Precis Cancer Med* 2, 29–29. <https://doi.org/10.21037/pcm.2019.09.04>
- Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. *Futur Oncol* 2010;6:1771–9. doi:10.2217/fon.10.127.
- Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature* 2002;418:934. doi:10.1038/418934a.
- Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na<sup>+</sup>/I<sup>-</sup> targeting to the membrane. *Endocr Relat Cancer* 2006;13:257–69. doi:10.1677/erc.1.01119.
- Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, et al. Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. *PLoS Med* 2013;10. doi:10.1371/journal.pmed.1001380.
- Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, et al. BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma. *Clin Cancer Res* 2006;12:1623–9. doi:10.1158/1078-0432.CCR-05-2378.
- Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of



- Anaplastic Thyroid Cancer. *Clin Cancer Res* 2004;10:8594–602. doi:10.1158/1078-0432.CCR-04-0690.
- Schulten, H.-J., Salama, S., Al-Mansouri, Z., Alotibi, R., Al-Ghamdi, K., Al-Hamour, O.A., Sayadi, H., Al-Aradati, H., Al-Johari, A., Huwait, E., Gari, M., Al-Qahtani, M.H., Al-Maghrabi, J., 2012. BRAF mutations in thyroid tumors from an ethnically diverse group. *Hered Cancer Clin Pract* 10, 10. <https://doi.org/10.1186/1897-4287-10-10>
- Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini CL. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. *Ann Oncol Off J Eur Soc Med Oncol* 2009;20:1728–35. doi:10.1093/annonc/mdp050.
- Seib, C.D., Sosa, J.A., 2019. Evolving Understanding of the Epidemiology of Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America* 48, 23–35. <https://doi.org/10.1016/j.ecl.2018.10.002>
- Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. *Ann Surg Oncol* 1996;3:534–8.
- Sharma A, Jasim S, Reading CC, Ristow KM, Villasboas Bisneto JC, Habermann TM, et al. Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. *Thyroid* 2016;26:1061–7. doi:10.1089/thy.2016.0095.
- Siegel RL, Miller KD, Jemal A. Cancer statistics of American 2019. *CA Cancer J Clin* 2019. doi:10.3322/caac.21551.
- Sithanandam G, Kolch W, Duh FM, Rapp UR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. *Oncogene* 1990;5:1775–80.
- Smallridge Robert C, Ain Kenneth B, Asa Sylvia L, Bible Keith C, Brierly James D, Burman Kenneth D, Kebebew Electron, Lee Nancy Y, Nikiforov Yuri E, Rosenthal M Sara, Shahm Manisha H, Shaha Ashok R, Tuttle R Michael, et al. American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. *THYROID* Volume 22, Number 11, 2012. doi: 10.1089/thy.2012.0302.



- Souza Rosário PW, Alvarenga Fagundes T, Villas-Boas Fagundes AS, Barroso AL, Lamego Rezende L, Lanza Padrão E, et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. *Exp Clin Endocrinol Diabetes* 2005;113:331–3. doi:10.1055/s-2005-837666.
- Trovisco V, Soares P, Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. *Hum Pathol* 2006;37:781–6. doi:10.1016/j.humpath.2006.03.013.
- Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, et al. Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function. *Thyroid* 2010;20:257–63. doi:10.1089/thy.2009.0401.
- La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. *Int J Cancer* 2015;136:2187–95. doi:10.1002/ijc.29251.
- Vannucchi, G., De Leo, S., Perrino, M., Rossi, S., Tosi, D., Cirello, V., Colombo, C., Bulfamante, G., Vicentini, L., Fugazzola, L., 2015. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. *European Journal of Endocrinology* 173, 29–36. <https://doi.org/10.1530/EJE-15-0054>
- Vuong HG, Kondo T, Duong UNP, Pham TQ, Oishi N, Mochizuki K, et al. Prognostic impact of vascular invasion in differentiated thyroid carcinoma: a systematic review and meta-analysis. *Eur J Endocrinol* 2017;177:207–16. doi:10.1530/EJE-17-0260.
- Wells Samuel A. Jr., Asa Sylvia L, Dralle Hening, Elisei Rossella, Evans Douglas B, Gagel Robert F, Nancy Lee, Machens Andreas, Moley Jeffrey F, PaciniFurio, Raue Friedhelm, Frank-Raue Karin, Robinson Bruce, Rosenthal M. Sara, Sanoro Massimo, Schlumberger Martin, Manisha Shah, Waguespack Steven G. Revised American Thyroid Association Guidelines for the Management of Meddular Thyroid Carcinoma. 2015. The American Thyroid Association Guidelines Task Force on Medullary



Thyroid Carcinoma. doi :10.1089.

WHO. World Health Organization Classification of Tumours : Pathology and Genetics of Tumours of Endocrine Organs 2004:50–2.

Wong DJL, Ribas A. Targeted Therapy for Melanoma. *Cancer Treat. Res.*, vol. 167, 2016, p. 251–62. doi:10.1007/978-3-319-22539-5\_10.

Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. *J Clin Endocrinol Metab* 2005;90:6373–9. doi:10.1210/jc.2005-0987.

Zhang, Q., Liu, S., Zhang, Q., Guan, Y., Chen, Q., Zhu, Q., 2016. Meta-Analyses of Association Between **BRAF**<sup>V600E</sup> Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. *Cell Physiol Biochem* 38, 763–776. <https://doi.org/10.1159/000443032>